Murphy & Mullick Capital Management’s GSK GSK Stock Holding History

Murphy & Mullick Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36.1K	Hold	689	–	–	0.02%	341
2026 Q1	$38K	Hold	689	–	–	0.03%	320
2025 Q4	$33.8K	Hold	689	–	–	0.02%	341
2025 Q3	$29.7K	Sell	689 -66	-9%	-$2.58K	0.02%	341
2025 Q2	$28K	Buy	755 +66	+10%	+$2.52K	0.02%	335
2025 Q1	$26.7K	Hold	689	–	–	0.03%	334
2024 Q4	$23.3K	Buy	+689	New	+$24.8K	0.02%	344

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Murphy & Mullick Capital Management's GSK Position: Q2 2026 in Review

Murphy & Mullick Capital Management held its GSK (GSK) position steady in Q2 2026 at 689 shares worth $36.1K. The position accounts for 0.02% of the portfolio, ranked #341.

Murphy & Mullick Capital Management first reported a position in GSK in Q4 2024 and has held it in 7 quarters since. The position peaked at $38K in Q1 2026. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Murphy & Mullick Capital Management held 689 shares of GSK worth $36.1K as of Q2 2026.
Murphy & Mullick Capital Management left its GSK share count unchanged in Q2 2026.
GSK made up 0.02% of Murphy & Mullick Capital Management's portfolio in Q2 2026, its #341 holding.
Murphy & Mullick Capital Management first reported a position in GSK in Q4 2024 and has held it in 7 quarters since.
Murphy & Mullick Capital Management's GSK position peaked at $38K in Q1 2026.
1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.